Monday, November 7 2016
Today's Research Daily features new research reports on 16 major stocks, including ExxonMobil (NYSE:XOM), Gilead (GILD) and Duke Energy (NYSE:DUK).
ExxonMobil shares have lagged the broader energy space this year (the stock is up 7.2% year to date vs. 12% gain for the sector as a whole), reflecting the stock's defensive attributes and relatively less 'oiliness' relative to peers like Chevron (NYSE:CVX). The stock is nevertheless ahead of the market this year and provides a lower risk way to play the energy space with its integrated model, above peer group average financial returns, a fortress balance sheet and a very safe and attractive dividend currently 3.6%. Exxon's Q3 results were significantly below the year-earlier level, but they were nevertheless better than expected. Comparisons are expected to improve from Q4 onwards. (You can read the full research report on ExxonMobil here>>)
Gilead shares have been laggards this year, losing nearly 28% year-to-date, as the HCV franchise continues to witness slowdown in the U.S. and Europe due to lower sales of Harvoni. The mixed Q3 results and questions about product pipeline didn't help matters either. On top of this are macro headwinds facing all drug makers related to pricing and other regulatory changes that many suspect are steadily shifting in an unfavorable direction. These are no doubt big challenges, but the analyst also points towards the company's robust late-stage pipeline. (You can read the full research report on Gilead here>>)
Duke Energy shares have outperformed the broader market as well as the peer utilities space in the year-to-date period (it is up more than 8%), with the company's better than expected Q3 results adding to the favorable momentum. The analyst likes the company’s strong cash position, as is evident from the solid improvement in its cash equivalents figure. Further, the company’s updated guidance buoys optimism. Being a premier utility service provider, Duke Energy continues to invest in infrastructure and expansion projects. Going ahead, stringent environmental regulations, pending regulatory cases, volatile commodity prices, severe weather patterns and foreign exchange risks may hinder Duke Energy’s performance. (You can read the full research report on Duke Energy here>>)
Other noteworthy reports we are featuring today include Regeneron (REGN), NVIDIA (NASDAQ:NVDA) and Monster Beverage (NASDAQ:MNST).
Today's Private Buys & Sells from Zacks Research
While we share the above news with the public, our sensitive recommendations are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trades >>
Sheraz Mian
Director of Research
Note: If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Featured Reports
Regeneron (REGN) Tops Q3 Earnings Estimates, Misses on Sales
Regeneron's Q3 results were mixed with the company beating on earnings but revenues falling short of expectations. The Zacks analyst feels that Eylea should continue to contribute to the top line.
Valero Energy (NYSE:VLO) Beats on Q3 Earnings Estimates
The covering analyst believes that lower operational expenses drove Valero's better-than-expected third-quarter earnings. However, the bottom line fell year over year due to weak gasoline margin.
Anthem (ANTM) Missed on Q3 Earnings on Higher Expenses
The Zacks analyst believes wide product portfolio, divestitures, prudent capital management, modest cash position, strategic acquisitions and ACO arrangements position Anthem for long-term growth.
Cigna (NYSE:CI) Beats Earnings and Revenue Estimates in Q3
The company's results reflect strong performance in its Commercial Health Care and Global Supplemental Benefits businesses and improving results in its Group Disability and Life segment.
LinkedIn (NYSE:LNKD) Q3 Results Indicate Strong Momentum Ahead
The Zacks analyst believes that LinkedIn's continued investments for providing new products and services will drive member growth and user engagement.
Currency Hurts Clorox's (CLX) Q1 Earnings
The Zacks analyst thinks Clorox's first-quarter earnings were hurt by currency woes and higher manufacturing and logistics costs.
Shire (SHPG) Lags Q3 Earnings & Revenues, Maintains View
The covering analyst thinks strong performance of Vyvanse, Lialda, and Firazyr should help offset the decline in Cinryze.
New Upgrades
Zoetis (ZTS) Tops Q3 Earnings Estimates, Raises Outlook
Zoetis' Q3 results were strong with the company beating on both fronts. The Zacks analyst believes that the raised outlook for 2016 is achievable based on the performance of its companion animal unit.
NVIDIA (NVDA) Rides High on Innovative Product Pipeline
The covering analyst thinks that NVIDIA's sustained focus on developing innovative products for the gaming, datacenter and automobile sectors will continue to drive its top and bottom line results.
First Republic (FRC) Focuses on Driving Organic Growth
The Zacks analyst remains optimistic after management's comments in its Investor Day that reflected bullish tone. It continues to expect EPS growth including 50% loan growth from existing clients.
New Downgrades
Lions Gate (LGF) Q2 Net Income Falls, Escalating Costs Worrying
Lions Gate's adjusted net income fell in second-quarter fiscal 2017. The Zacks analyst thinks escalating cost of motion picture production and marketing in recent years may jeopardize Lions Gate's margins.
Monster Beverage (MNST) Q3 Earnings Miss Expectations
Monster Beverage missed the top and bottom-line estimates in the third quarter. Soft third-quarter results with slow U.S. growth raise concerns, per the covering analyst.
Franklin's (BEN) Q4 Results Show Revenue Stress as AUM Falls
According to the Zacks analyst, though fiscal Q4 results reflected continued cost management, a key concern remains over the decline in assets under management, indicating pressure on top line.
EXXON MOBIL CRP (XOM): Free Stock Analysis Report
REGENERON PHARM (REGN): Free Stock Analysis Report
NVIDIA CORP (NVDA): Free Stock Analysis Report
MONSTER BEVERAG (MNST): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
DUKE ENERGY CP (DUK): Free Stock Analysis Report
Original post
Zacks Investment Research